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revisited
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Abstract
The past two decades have witnessed an increasing appreciation of the role of the tumor microenvironment, of 
genetic and epigenetic alterations in normal cells adjacent to tumors and of the migration of normal cells with 
aberrant intrinsic properties in cancer pathophysiology. Aside from these insights, a novel concept termed 
"oncoprotein metastasis" (OPM) has recently been advanced and proposed to reflect protein-based neoplastic 
phenomena that might occur even before any modifications relating to the morphology, location or (epi)genetic outfit 
of cells during the malignant process. Here, evidence is presented that supports the OPM perception and thus should 
contribute not only to further rethink the definition of a normal cell, but also the treatment of cancer disease in the 
years to come.
Background
Over the past decades of molecular cancer research,
many investigators have strived to understand the single
subcellular alterations that make a normal cell switch to
become a cancer cell. One of the first key advances along
these lines was the detection of a minute chromosome in
chronic myelogenous leukemia cells [1]. Subsequently,
many more aberrant chromosomes resulting from chro-
mosomal alterations such as translocations and deletions
were identified in various malignant diseases, mainly
affecting the hematological lineage. A corollary of this
view on a chromosomal origin of neoplasias was the pos-
tulate according to which cancer arises from chromo-
somal aberrations occurring in single cells that, due to
these pathological subcellular changes, start proliferating
in a clonal fashion giving rise to macroscopic tumors [2].
Historically intersecting with this perception was the
uncovering in normal DNA of cellular oncogenes resem-
bling their viral counterparts [3] which marked the begin-
ning of the (proto)oncogene paradigm in cancer research
according to which (amplified) oncogenes drive cancer
cell proliferation. On the other hand, alterations in a sec-
ond class of genes, more specifically partial or complete
losses of tumor suppressor genes in tumor cells [4] and,
as was found a number of years later, also in (morpholog-
ically) normal cells adjacent to primary tumors [5] were
equally recognized as paramount in the pathogenesis of
neoplasias.
These chromosomal and genetic alterations as well as
aneuploidic sets of chromosomes are widely believed
until nowadays to underlie the neoplastic transformation
of normal cells into morphologically overt cancer cells
although a recent re-evaluation of this aspect has
revealed that aneuploidy can under certain conditions
have also the opposite effect of tumor suppression [6].
Notwithstanding these significant leaps in our knowledge
on cancer, this disease remained largely undefeated by the
end of the 1990s [7] and has stayed so in its metastatic
form until even today, despite recent drug achievements
such as herceptin and imatinib that each target the prod-
uct of an altered oncogene. The reason why a genuine
therapeutic breakthrough remains as yet unachieved [8]
could likely be that our strategies to tackle cancer are still
incompletely integrating the many pieces of the puzzle
that we have already accumulated and the various con-
cepts already advanced on the basis of this knowledge.
In accordance with this interpretation, Richmond
Prehn asked already in 1994 [9] the crucial hen-and-egg
question on cancer pathogenesis as to what comes first:
the cancer process per se or the mutations in genes per-
taining to morphologically overt cancer cells? This call
for a possible paradigm shift remains a challenge until
today, yet some key elements of such malignant process
can be already found in the literature of the past two
decades. Accordingly, it has been observed that the can-
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cer process may begin very early, specifically at the level
of the DNA structure in (morphologically) normal cells
adjacent to primary tumors [10]. Furthermore, it was
concluded that certain post-translational events that
inactivate a given tumor suppressor protein could be
regarded as functionally equivalent to an inactivating
mutation of its gene, for instance retinoblastoma protein
(RB)'s physical interaction with a viral oncoprotein or the
former's hyperphosphorylation [11]. Post-translational
events such as the increase in the stability of an oncopro-
tein were equally recognized as crucial for a pathologi-
cally accelerated cell cycle progression [12]. Moreover, it
was found that hypermethylations in the promoters of
genes encoding growth-suppressive proteins often mimic
the patterns for mutations in the respective genes [13].
Also, the phenomenon of nuclear exclusion of tumor sup-
pressors through their cytoplasmic sequestration by dis-
tinct proteins has been recognized as another mechanism
corresponding to an inactivating mutation of the respec-
tive tumor suppressor gene [14,15]. In addition, protein-
based inflammatory processes in the tumor microenvi-
ronment are likely to influence the tumor cells embedded
in that specific area [16]. The key twist common to these
molecular insights is that the post-translational/epige-
netic events they refer to may conceivably occur in mor-
phologically normal cells that, moreover, have not yet
acquired modifications in their growth-regulatory genes,
yet these events might already constitute a (pre)malig-
nant process that is ongoing in these seemingly normal
cells.
Oncoprotein metastasis disjoined: a reappraisal
Several years ago, I have expanded this view by my con-
cept on an oncoprotein metastasis (OPM) and its possible
therapeutic reversal [17,18]. In analogy to the possibilities
of a transfer of disease from one organ site to another, i.e.
of metastasis by means of a) microorganisms, e.g. bacteria
[19], or b) cells, e.g. (morphologically) malignant cells
[20] or, as shown after the above-mentioned oncoprotein
metastasis concept had been advanced, even (morpho-
logically) normal/untransformed cells [21], I have pro-
posed a third mechanism (Fig. 1a) according to which
growth-promoting  proteins  such as insulin that are
known to be capable of translocating across cellular
membranes may equally convey, if present in abnormal
tissue concentrations, initial pathologic signals to proxi-
mal and distant tissues and thus contribute to their malig-
nant transformation prior to the occurrence of any
(epi)genetic and/or chromosomal alterations [17,18].
Thereby, I had also surmised that defective tumor-sup-
pressive mechanisms in such OPM-affected tissues would
partly account for the differential organ preference of var-
ious tumor metastases [17].
Interestingly, this novel putative mechanism not only
relates in part to a long-standing (protein deletion) theory
advanced in the pre-molecular era of cancer research
[22], but may also account for the increased probability of
distant metastasis and extensive-stage disease correlating
with poor outcome in tumor patients in which an ectopic
hormone production (along with a paraneoplastic syn-
drome) has been ascertained [23-25].
Although this insight on a possible oncoprotein metas-
tasis-that had been based primarily on many preceding
studies on the hyperinsulinemia-cancer connection and
on the presence of insulin in tumor cells-is still relatively
new, there have been recent experimental reports that
provide further support for this assumption. As such, the
recent demonstration of the ability of the E1A viral onco-
protein to epigenetically reprogram the cells it infects
[26], makes it conceivable that insulin-which shares with
E1A the LXCXE RB-binding motif [27] along with the
capacity to bind [28-30] and thereby inactivate RB [28]-
reprograms the genes of the cells it has entered for abnor-
mal cell proliferation. These potential insulin-induced
epigenetic changes would functionally mimic both a (pre-
ceding) growth-promoting effect of an insulin-RB com-
plex formation and a (subsequent) gene mutation pattern
that may arise during the further evolution of these cells/
tissues towards malignancy. In other words, the viral
oncoprotein-like insulin molecule [27,31] would display
two distinct properties that are functionally equivalent in
terms of driving oncogenesis [18]. Moreover, the immu-
nohistochemical identification of insulin in lung cancer
tissue samples (whereby, besides the actual tumor cells,
some normal pneumocytes were also revealed to be insu-
lin-positive) in the absence of detectable insulin tran-
scripts [32] additionally strengthens the concept of a
pathological spread of (blood-borne) insulin in malignant
diseases.
Beyond insulin, there are also other candidate mole-
cules that could undergo an oncoprotein metastasis, e.g.
osteopontin. Accordingly, it has been shown that osteo-
pontin is found in premalignant and malignant cells
derived from patients with tumors of the oral cavity [33]
and, moreover, that osteopontin translocates to the nuclei
of mitotic cells [34]. Entirely consistent with the oncopro-
tein metastasis concept and intriguingly, it has further-
more been shown that primary tumor-derived and blood-
borne osteopontin is able to promote the microenviron-
mental changes necessary for distant metastatic seeds
[35].
Most recently, a known amino acid labeling technique
has been extended to investigate intercellular communi-
cation via both secreted and internalized proteins such as
metastasis associated protein 3 and retinoblastoma bind-
ing protein 7 [36]. It will therefore be interesting to probe
in future studies as to whether these proteins can add toRadulescu Journal of Experimental & Clinical Cancer Research 2010, 29:30
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insulin and osteopontin as mediators of the proposed
oncoprotein metastasis phenomenon.
Since it thus appears that that there are various proteins
that cross subcellular borders and thereby contribute to
carcinogenesis, a therapeutic strategy that suggests itself
in order to counteract these microbial infection-like,
transcellular processes of malignancy would be to admin-
ister cell-permeable agents that directly block these
mobile oncoproteins. Possible pharmacological candi-
dates for such intervention are cell-penetrating tumor
suppressor peptides, in particular those targeting the RB
and nucleocrine pathways [17,18,28,30,37-40]. In this
context, a parallel is noteworthy: in the same way as insu-
lin's internalization into cells is not saturable [41] nor is
that of a 16-amino acid fragment derived from the Anten-
napedia homeodomain and termed "Penetratin" either
[42]. Hence, the use of the latter in the construction of the
above-mentioned anticancer peptides [30,37,38] in order
to counteract insulin-driven cell proliferation is likely to
ensure (under appropriate pharmacodynamic and phar-
macokinetic conditions) the achievement of a pharmaco-
Figure 1 Schematic definition of the process of oncoprotein metastasis (OPM) accompanied by physical interactions between oncopro-
teins (OPs) and tumor suppressor proteins (TSPs): a) spatially, consisting in the local, tissular penetration of OPs into cells adjacent to the cells from 
which the OPs originate (thereby extending the paracrine principle) and/or their systemic spread via blood and lymphatic vessels to distant tissues/
organs (thereby extending the endocrine principle), each of which would be ensued by (e.g. nucleocrine [28,31]) OP-TSP complex formations (OP × 
TSP); it should be also stated here that the OP-secreting cells are not necessarily tumor cells, but could be normal cells, e.g. pancreatic β-cells that 
secrete (excessive amounts of) insulin in response to (blood-borne) tumoral stimuli and thus cause a well-known (cancer-associated) state of hyper-
insulinemia; b) temporally, consisting in the OPM-associated and carcinogenesis-initiating event of OP-TSP complex formations (OP × TSP) that pre-
cede the epigenetic silencing of the corresponding tumor suppressor gene-caused by the hypermethylation of its promoter-which in turn is 
subsequently functionally mimicked by a loss of heterozygosity (LOH) of the same gene, all of which changes would occur in (morphologically) normal, 
yet likely premalignant cells.
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logical balance which represents one of the prerequisites
if oncoprotein metastasis is to be reversed.
Implications for medicine
Taken together, I have presented additional recent evi-
dence for the potential occurrence of oncoprotein metas-
tasis that may be a major mechanism of premalignancy
besides and/or preceding epigenetic and genetic changes
in morphologically normal cells (Fig. 1b and Fig. 2a). For
a complete picture it should be added that the process of
oncoprotein metastasis may also occur in malignant cells
and thereby contribute to their further de-differentiation.
Therefore, future studies should examine whether
(morphologically) normal cells from cancer patients, in
particular those adjacent to primary tumors and their
metastases, i.e. pertaining to their (inflammatory)
microenvironment [16], contain oncoprotein-tumor sup-
pressor protein heterodimers (Fig. 1b) or, respectively,
their correlates, e.g. posttranslational tumor suppressor
protein modifications such as RB (hyper)phosphoryla-
Figure 2 Schematic overview of possible sequelae of oncoprotein metastasis (OPM) and a potential OPM treatment with distinct antineo-
plastic peptides. a) Morphological sequelae of OPM and its (epi)genetic correlates ultimately making a seemingly normal cell adopt a malignant ap-
pearance ("morphological switch"). b) Molecular sequelae of OPM resulting in a tumor suppressor protein (TSP) loss of function (after a reactive or 
compensatory upsurge in response to the initial oncoprotein challenge) already at an early stage of the oncogenic process when the affected cells 
have still a (deceivingly) normal appearance ("functional switch"). c) Antagonism of OPM by treatment (Rx) with TSP-like peptides featuring a binary 
structure that combines an antiproliferative (AP) segment with a nuclear localization sequence (NLS) the latter of which also mediates cellular pene-
tration/internalization and thus ensures that these antineoplastic peptides are able to enter and influence both (premalignant) normal-appearing cells 
and cancer cells. For a more complete picture, it should be added that non-peptide mimetics of these peptides are also conceivable (albeit, for specific 
reasons to be discussed elsewhere, not preferred) therapeutics. Moreover, chemopreventive (peptide and non-peptide) agents are likely to achieve 
their beneficial effects by a similarly global internalization into non-malignant and premalignant cells.
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tions [17]. For investigative purposes, this protein-based
status of cancer patient-derived normal cells should be
additionally compared with alike parameters of normal
cells obtained from non-cancer patients and also from
healthy individuals.
This proposed analysis, if validated, should fundamen-
tally transform the diagnosis, prognosis and treatment of
malignant disease. As previously outlined [43], such novel
approach would, for instance, entail a profound revision
of the surgical management of this ailment as R0 resec-
tions, i.e. tumor resections into healthy surrounding tis-
sue, would no longer be determined by the morphology
of the cells only, but also by the subcellular  (protein-
based, epigenetic and genetic) status  of the normal-
appearing cells surrounding the primary tumor and/or
metastasis, respectively. The consequence therefrom
would be more precise surgical resections (guided by
prior subcellular analysis) which in turn should reduce
the rate of local recurrence of primary tumors, e.g. of
advanced stage (colo)rectal carcinomas.
Furthermore, given the loss of function of tumor sup-
pressor proteins coinciding with an oncoprotein metasta-
sis and its (epi)genetic correlates (Fig. 2b), drug treatment
of cancer disease could equally undergo a paradigm shift
through the application of cell-permeable tumor suppres-
sor peptides that enter both morphologically normal, yet
likely premalignant cells and cancer cells (Fig. 2c), as pre-
viously envisaged [17,18,39,40,44]. This potential phar-
macological rationale would address not only the primary
tumor, but also its distant metastases in an appropriate
fashion, specifically by disrupting oncoprotein-tumor
suppressor protein heterodimers and thereby reactivating
tumor suppressor function in the entire organism. Hence,
the survival of the cancer patient which depends primar-
ily on the extent of successful eradication of tumor
metastasis would be predictably increased.
The above-proposed therapeutic approach by means of
antineoplastic, cell-permeable peptides would have
bionic features as it would reflect some properties of nat-
ural molecules which combine antiproliferative proper-
ties with a propensity to shuttle in and out of cells such as
interferons [39], e.g. γ-interferon [45], insulin-like growth
factor binding protein (IGFBP) 3 [46,47] and the IGFBP-
related HtrA1 gene product [48]. In the same way as these
defensive proteins contribute to the homeostasis of cell
growth, so would their artificial peptide mimetics
whereby these synthetic molecules could be titrated such
that the growth acceleration excess would be curtailed,
yet not the entire proliferative process per se ablated, con-
sistent with a previously proposed artificial induction of
homeostatic defense mechanisms [49] and also a more
recent view cautioning against the side effects of a com-
plete abrogation of a given disease target [50].
Ramifications for biophysics
It is furthermore interesting to note that non-malignant
cells in which tumor suppressor function is compromised
by a) putatively oncoprotein metastasis along with onco-
protein-tumor suppressor protein complex formations,
b) epigenetic silencing through hypermethylation of the
promoters of tumor suppressor genes or, respectively, c)
tumor suppressor gene LOH may be regarded as (energet-
ically) distinct quantum states of a (morphologically) nor-
mal cell whereby an intrinsic (premalignant) evolution of
this cell towards the latter state, i.e. the most entropic and
thus most stable or least reversible one, could be assumed
Figure 3 Schematic representation of the increase in entropy (S) associated with premalignant, subcellular changes over time and its po-
tential reversal. More specifically, S gradually increases from the state of oncoprotein metastasis (OPM) in conjunction with oncoprotein (OP)-tumor 
suppressor protein (TSP) complex formations (OP × TSP) to the state of (epigenetic) tumor suppressor gene (TSG) promoter hypermethylations 
(hyperCH3) and again to the state of TSG loss of heterozygosity (LOH) defects, whereby each of their neutralization requires a corresponding amount 
of energy (E) or negative entropy, respectively, intrinsic to a given dose of a therapeutic compound (Rx). In this context, it should be specified that the 
(premalignant) stages of an OPM encompassing OP-TSP complex formations and of its epigenetic equivalent may be subject to a relatively high de-
gree of spontaneous reversibility through natural mechanisms of cancer surveillance.
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(Fig. 3). This view would thus expand on a previous bio-
physical concept postulating (molecular) entropy as a key
driving force for carcinogenesis [51] and, moreover, be in
line with observations on the (prognostically adverse)
structural entropy of lung tumors [52] and the entropic
accumulation of splicing defects in various carcinomas
[53].
As a result, these premalignant processes might be
reversed-in a dose-dependent fashion corresponding to
distinct energy (or negative entropy) values (Fig. 3) - by
antagonistic quantum states induced e.g. by therapeutic
cell-permeable peptides in conjunction with the growth-
suppressive function of endogenous proteins that these
peptides may recruit through physical interactions
[17,43,54]. In accordance with this view, it has been
shown for a series of antineoplastic compounds including
peptides that the inhibition of cell cycle progression
ensuing from the disruption of protein-protein interac-
tions requires a lower dose of the respective anticancer
agent as compared to that at which (programmed) cell
death (e.g. by nuclear fragmentation) occurs in cancer
cells.
Moreover, the energetic or quantum states of untreated
vs. treated (pre)malignant cells should be explored by
physical methods, thus considerably expanding on mea-
surements of quantum states in elements used by living
systems such as shown for photosynthetic reactions
[55,56]. These envisioned advances may not only be deci-
sive for the further refinement and increased precision of
diagnosis and therapy of cancer disease, e.g. by means of
sequential mapping and targeting of neoplastic "fields"
[5,17,51], but also further substantiate the insights of Del-
brück et al. at the interface between biology and physics
[57], ultimately making it likely that quantum biology will
come of age in the foreseeable future.
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